EA201101035A1 - NEW CONJUGATE OF GRANULOCITAR COLONIUS STIMULATION FACTOR (G-CSF) WITH POLYETHYLENE GLYCOL - Google Patents

NEW CONJUGATE OF GRANULOCITAR COLONIUS STIMULATION FACTOR (G-CSF) WITH POLYETHYLENE GLYCOL

Info

Publication number
EA201101035A1
EA201101035A1 EA201101035A EA201101035A EA201101035A1 EA 201101035 A1 EA201101035 A1 EA 201101035A1 EA 201101035 A EA201101035 A EA 201101035A EA 201101035 A EA201101035 A EA 201101035A EA 201101035 A1 EA201101035 A1 EA 201101035A1
Authority
EA
Eurasian Patent Office
Prior art keywords
csf
granulocitar
colonius
polyethylene glycol
conjugate
Prior art date
Application number
EA201101035A
Other languages
Russian (ru)
Other versions
EA019043B1 (en
Inventor
Татьяна Вениаминовна ЧЕРНОВСКАЯ
Лев Александрович Денисов
Дмитрий Валентинович МОРОЗОВ
Елена Георгиевна Руденко
Елена Леонидовна Морозова
Original Assignee
Закрытое Акционерное Общество "Биокад"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45567857&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201101035(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Закрытое Акционерное Общество "Биокад" filed Critical Закрытое Акционерное Общество "Биокад"
Publication of EA201101035A1 publication Critical patent/EA201101035A1/en
Publication of EA019043B1 publication Critical patent/EA019043B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Изобретение относится к фармацевтике и медицине, а именно к новым физиологически активным конъюгатам гранулоцитарного колониестимулирующего фактора (Г-КСФ) общей формулы:где n - целые значения от 227 до 1 000; m представляет собой целое число ≥4; NαH-Г-КСФ - представляет собой гранулоцитарный колониестимулирующий фактор. Также изобретение относится к лекарственным средствам, содержащим заявляемый коньюгат формулы (I), фармацевтическим композициям, применению коньюгата формулы (I) для получения лекарственного средства и лекарственным средствам, обладающим активностью гранулоцитарного колониестимулирующего фактора, способу профилактики и/или лечения нейтропении, контейнеру, включающему фармацевтическую композицию или лекарственное средство, и набору.The invention relates to pharmaceuticals and medicine, namely to new physiologically active conjugates of granulocyte colony-stimulating factor (G-CSF) of the general formula: where n is integer values from 227 to 1 000; m is an integer ≥4; NαH-G-CSF - is a granulocyte colony-stimulating factor. The invention also relates to medicinal products containing the claimed conjugate of formula (I), pharmaceutical compositions, the use of a conjugate of formula (I) for preparing a medicinal product and medicinal products having granulocyte colony-stimulating factor activity, a method of preventing and / or treating neutropenia, a container including a pharmaceutical composition or drug and kit.

EA201101035A 2010-08-13 2011-08-01 A novel conjugate of granulocyte colony-stimulating factor (g-csf) with polyethylene glycol EA019043B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2010133875/10A RU2446173C1 (en) 2010-08-13 2010-08-13 New functional, high-purity stable conjugate of granulocyte colony-stimulating factor (g-csf) and polyethylene glycol with prolonged biological action, applicable for medical purposes, and based immunobiological agent

Publications (2)

Publication Number Publication Date
EA201101035A1 true EA201101035A1 (en) 2012-02-28
EA019043B1 EA019043B1 (en) 2013-12-30

Family

ID=45567857

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201101035A EA019043B1 (en) 2010-08-13 2011-08-01 A novel conjugate of granulocyte colony-stimulating factor (g-csf) with polyethylene glycol

Country Status (17)

Country Link
KR (1) KR101549457B1 (en)
CN (1) CN103140499B (en)
CL (1) CL2013000400A1 (en)
CO (1) CO6670557A2 (en)
CR (1) CR20130020A (en)
CU (1) CU24139B1 (en)
DO (1) DOP2013000003A (en)
EA (1) EA019043B1 (en)
EC (1) ECSP13012399A (en)
MA (1) MA34525B1 (en)
MY (1) MY160732A (en)
NI (1) NI201300007A (en)
PE (1) PE20131085A1 (en)
RS (1) RS20130094A1 (en)
RU (1) RU2446173C1 (en)
SG (1) SG187572A1 (en)
WO (1) WO2012021088A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10286039B2 (en) 2014-02-18 2019-05-14 Children's Hospital Los Angeles Compositions and methods for treating neutropenia
US11116738B2 (en) 2012-06-07 2021-09-14 Children's Hospital Los Angeles Methods for treating neutropenia using retinoid agonists

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012110057A1 (en) 2011-02-15 2012-08-23 Chemisches Institut Schaefer Ag Cefuroxime safety kit
CN103908427B (en) * 2013-01-05 2014-12-17 石药集团百克(山东)生物制药有限公司 Polyethylene glycol modified rhG-CSF injection and preparation method thereof
RU2535002C2 (en) * 2013-04-04 2014-12-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук Method for correction of remote consequences of spermatogenesis caused by cytostatic exposure
JP6742300B2 (en) * 2014-07-14 2020-08-19 ジェンノヴァ バイオファーマシューティカルズ リミテッド Novel process for purification of rHu-GCSF
IL247369B (en) * 2016-08-18 2018-08-30 B G Negev Tech And Applications Ltd Modified m-csf polypeptides and use thereof
KR102020995B1 (en) * 2017-10-30 2019-09-16 한국코러스 주식회사 A method of preparing gcsf and polyol_conjugated conjugates with high yield
BR112022018501A2 (en) * 2020-03-17 2022-10-25 Drugrecure Aps LIQUID FORMULATION OF GM-CSF FOR INHALATION

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE135370T1 (en) * 1988-12-22 1996-03-15 Kirin Amgen Inc CHEMICALLY MODIFIED GRANULOCYTE COLONY EXCITING FACTOR
US5252714A (en) * 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
KR20040083268A (en) * 2003-03-21 2004-10-01 한미약품 주식회사 Human granulocyte-colony stimulating factor conjugate having enhanced stability in blood and process for the preparation thereof
RU2278870C2 (en) * 2004-08-30 2006-06-27 Закрытое Акционерное Общество "Биокад" Method for preparing, isolating, purifying and stabilizing human recombinant granulocytic colony-stimulating factor useful for medicinal using and immunobiological agent based on thereof
WO2007084460A2 (en) * 2006-01-18 2007-07-26 Qps, Llc Pharmaceutical compositions with enhanced stability
JP2009541333A (en) * 2006-06-23 2009-11-26 クインテセンス バイオサイエンシーズ インコーポレーティッド Modified ribonuclease

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11116738B2 (en) 2012-06-07 2021-09-14 Children's Hospital Los Angeles Methods for treating neutropenia using retinoid agonists
US10286039B2 (en) 2014-02-18 2019-05-14 Children's Hospital Los Angeles Compositions and methods for treating neutropenia

Also Published As

Publication number Publication date
CU24139B1 (en) 2015-12-23
RU2446173C1 (en) 2012-03-27
CO6670557A2 (en) 2013-05-15
PE20131085A1 (en) 2013-10-10
DOP2013000003A (en) 2013-07-31
CN103140499A (en) 2013-06-05
MA34525B1 (en) 2013-09-02
KR101549457B1 (en) 2015-09-02
SG187572A1 (en) 2013-03-28
MY160732A (en) 2017-03-15
WO2012021088A1 (en) 2012-02-16
ECSP13012399A (en) 2013-05-31
NI201300007A (en) 2014-05-26
KR20130043167A (en) 2013-04-29
EA019043B1 (en) 2013-12-30
CN103140499B (en) 2014-12-17
CL2013000400A1 (en) 2013-07-26
RS20130094A1 (en) 2013-08-30
CR20130020A (en) 2013-02-20
CU20130012A7 (en) 2013-04-19

Similar Documents

Publication Publication Date Title
EA201101035A1 (en) NEW CONJUGATE OF GRANULOCITAR COLONIUS STIMULATION FACTOR (G-CSF) WITH POLYETHYLENE GLYCOL
BR112013003045A2 (en) compound and pharmaceutical composition and uses thereof, sterile container and method for preparing pharmaceutical composition for administration
CY1119616T1 (en) HUMAN ANTI-DUMP DRUG CONSUMPTION AGAINST TISSUE
MX2012007410A (en) Novel antiviral compounds.
NZ605887A (en) Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of neuropathic pain
MX2015003653A (en) Benzoimidazole-carboxylic acid amide derivatives as apj receptor modulators.
EA201171376A1 (en) THYENO DERIVATIVES [2,3-B] PIRIDINE AS VIRUS REPLICATION INHIBITORS
PH12014502524B1 (en) Carboxylic acid compounds
MX2011013150A (en) Pharmaceutical composition for use in medical and veterinary ophthalmology.
CY1113269T1 (en) INDIAZOLYL AMID PRODUCT FOR THE THERAPEUTIC TREATMENT OF GLUCCORTIC MEDICINES
EA201291089A1 (en) METHOD FOR OBTAINING PHARMACEUTICAL PREPARATIONS INTENDED FOR ORAL ADMINISTRATION, CONTAINING ONE OR MORE ACTIVE INGREDIENTS AND CONTAINING COMPOSITIONS
FR2900404B1 (en) NOVEL IMIDAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS A MEDICINAL PRODUCT
TW200731975A (en) Novel combinations of medicaments for the treatment of respiratory diseases
EA201390984A1 (en) HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA
EA201590697A1 (en) DERIVATIVES OF KETAMINE
MY168784A (en) The new stable polyethylene glycol conjugate of interferon alpha,represented by one positional isomer
MX2022006519A (en) Polyethylene glycol conjugate medicament, preparation method therfor and use thereof.
EA200501870A1 (en) NEW IMODAZOL DERIVATIVES, METHOD OF THEIR PRODUCTION AND THEIR USE AS A MEDICINE
UA107349C2 (en) Imidazolidine-2,4-dione derivatives, and use thereof as a cancer drug
CY1115600T1 (en) Piperazines as Anthelmintic Agents
TW200740440A (en) Novel combinations of medicaments for the treatment of respiratory diseases containing long-acting beta-agonists and at least one additional active ingredient
MX2022015232A (en) Aqueous pharmaceutical composition of levilimab.
BR112012020415A2 (en) pharmaceutical composition for the prevention or treatment of osteoarthritis
WO2015027669A3 (en) Phenyl-substituted compound, pharmaceutical composition and uses thereof
BR0209138A (en) Use of pyridoindolone derivatives for drug preparation

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG RU